Raffles Associates - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.

Quarter-by-quarter ownership
Raffles Associates ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$1,873,532
-16.8%
1,587,739
-0.6%
2.48%
-18.0%
Q2 2023$2,252,812
-2.3%
1,597,739
+4.0%
3.03%
-3.5%
Q1 2023$2,305,419
+28.2%
1,536,9460.0%3.14%
+49.1%
Q4 2022$1,798,230
-23.5%
1,536,946
-26.1%
2.10%
-16.0%
Q3 2022$2,351,000
-22.9%
2,080,536
+7.8%
2.51%
-24.5%
Q2 2022$3,050,000
+51.7%
1,930,536
+47.8%
3.32%
+60.7%
Q1 2022$2,011,000
+51.0%
1,306,095
+140.3%
2.07%
+61.9%
Q4 2021$1,332,000
+464.4%
543,590
+480.8%
1.28%
+482.6%
Q3 2021$236,000
+90.3%
93,590
+114.7%
0.22%
+108.6%
Q2 2021$124,000
+21.6%
43,5900.0%0.10%
+1.0%
Q1 2021$102,00043,5900.10%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders